Clinical Trials Arena on MSN

Immuneering progresses MAPK inhibitor in lung and pancreatic cancer

The biotech will now take atebimetinib to mid- and late-stage trials in NSCLC and pancreatic cancer, respectively.
ascopubs.org

Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers

NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...
Nature

Mitogen-Activated Protein Kinase Signaling Pathways and Inhibitors

Mitogen-Activated Protein Kinase (MAPK) signalling cascades are fundamental to the regulation of numerous cellular processes, including stress response, inflammation, cell cycle control and apoptosis.
ascopubs.org

After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor–Positive Metastatic Breast Cancer

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...